CD34 and prostate carcinoma: Similar with our findings, disseminated prostate cancer cells inhibited CD34+ HSC engraftment and competed for HSC niche, whereas non-metastatic transformed prostate epithelial cells did not repress CD34+ HSC engraftment [30].